Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1975 Dec;75(3):353-62.
doi: 10.1017/s0022172400024414.

A new surface-antigen-adsorbed influenza virus vaccine. II. Studies in a volunteer group

A new surface-antigen-adsorbed influenza virus vaccine. II. Studies in a volunteer group

C W Potter et al. J Hyg (Lond). 1975 Dec.

Abstract

A group of 23 volunteers were each inoculated with 600 CCA of a new form of influenza virus A/England/42/72 vaccine; this vaccine consisted of purified haemagglutinin and neuraminidase antigens adsorbed to alhydrogel. No significant reactions to the vaccine were reported. Twenty-two volunteers produced increased titres of serum HI antibody, and all showed increased titres of NI antibody after immunization. Thus, for volunteers with no pre-immunization serum HI antibody, the geometric mean titre of serum antibody increased from 1/5 to 1/196 after immunization. Ten volunteers developed local neutralizing antibody after immunization; this antibody response was detected most frequently in volunteers who showed the greater serum antibody response to immunization, and in nasal washings with the higher concentrations of protein and IgA. Ten weeks after immunization, the vaccinees and a group of matched controls were inoculated intranasally with attenuated A/England/42/72 virus. Evidence of infection with the challenge virus was found in 14 of the control subjects and in one of the vaccinees. The results indicate that the surface-antigen-adsorbed vaccine induced high titres of serum antibody, and gave significant protection against challenge infection.

PubMed Disclaimer

References

    1. J Lab Clin Med. 1964 Jan;63:5-13 - PubMed
    1. J Immunol. 1962 Mar;88:320-9 - PubMed
    1. Proc Soc Exp Biol Med. 1967 Jul;125(3):683-6 - PubMed
    1. J Immunol. 1963 Oct;91:484-97 - PubMed
    1. J Hyg (Lond). 1975 Dec;75(3):341-52 - PubMed